ALZN is trading at $1.08 (5.85% down) in after-hours, extending recent weakness following a sharp drop tied to new Alzheimer’s trial data disclosures.
- Traders are digesting news regarding upcoming presentations of clinical and biomarker results for the company's lead investigational therapy.
- Sentiment remains cautious as the stock continues to react to the July 7, 2026 disclosures, which previously triggered a 15% intraday decline.